FDA clears breast cancer drug meant to be started before a scan shows relapse

The Food and Drug Administration on Friday granted accelerated approval to a breast cancer drug that is meant to be started based on a blood test, before scans show a tumor is growing again, in what the agency and independent researchers described as a shift in how resistant cancers are caught and treated.

The drug, camizestrant, will be sold under the brand name Etcamah and is made by AstraZeneca. The FDA cleared it in combination with a CDK4/6 inhibitor for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors have developed a specific resistance mutation, known as ESR1, while they were being treated with a standard first-line hormone therapy. It is the first cancer drug the agency has approved on the basis of a resistance mutation detected in a blood sample, ahead of any sign on a CT or bone scan that the disease is worsening.

The numbers

ESR1 mutations are not common when breast cancer is first diagnosed, showing up in fewer than 5 percent of patients with hormone receptor-positive metastatic disease, according to the FDA. But the mutations emerge as a form of acquired resistance: after a patient's cancer progresses on an aromatase inhibitor, the front-line hormone therapy usually paired with a CDK4/6 inhibitor, nearly 40 percent will have developed the mutation. Those are the patients the new approval targets, and the point of the newly authorized companion blood test, the Guardant360 CDx assay, is to find the mutation while a patient still looks stable on scans.

The approval rests on data from AstraZeneca's SERENA-6 trial, which enrolled 310 patients and tested a strategy of switching to camizestrant as soon as an ESR1 mutation turned up in the blood, rather than waiting for imaging to confirm the cancer had progressed. Patients who switched had a median progression-free survival of 16.0 months, compared with 9.2 months for those who stayed on their aromatase inhibitor, a reduction in the risk of progression or death of 56 percent, with a hazard ratio of 0.44. The trial also found that switching early delayed the point at which patients' quality of life measurably worsened, from a median of about 6.4 months to 23.0 months, by AstraZeneca's accounting. Grade 3 or higher side effects, mostly low blood cell counts tied to the CDK4/6 inhibitors, were more frequent in the camizestrant arm, at 60 percent versus 46 percent, though few patients in either group stopped treatment because of them.

Breast cancer remains the most commonly diagnosed cancer among American women. The American Cancer Society estimates 382,640 women will be diagnosed with the disease in 2026 and about 42,140 will die of it, according to the society's key statistics for breast cancer. A far smaller, but substantial, population lives with the disease once it has spread: an estimated 168,000 women in the United States are living with stage IV, metastatic breast cancer, according to figures compiled by the National Breast Cancer Foundation. Most metastatic breast cancer is hormone receptor-positive, meaning the tumor relies on estrogen to grow, which is the population eligible for the new drug once resistance emerges.

How the approach took shape

The idea behind Etcamah's approval is monitoring what is called circulating tumor DNA, or ctDNA, tiny fragments of a tumor's genetic material that shed into the bloodstream and can be picked up with a blood draw. Oncologists have used ctDNA testing for several years to look for resistance mutations after a scan already shows progression. SERENA-6 tested something different: drawing blood at routine intervals, alongside scheduled scans, to catch the ESR1 mutation the moment it appeared and switch therapy immediately, before the cancer had visibly worsened.

Results from the trial were first presented at last year's American Society of Clinical Oncology meeting and published simultaneously in the New England Journal of Medicine. The FDA's Oncologic Drugs Advisory Committee reviewed the application on April 30, 2026, and the drug secured approval in the European Union earlier this year before Friday's U.S. clearance. Camizestrant belongs to a class of drugs called oral selective estrogen receptor degraders, which block and break down the estrogen receptors that hormone-driven tumors depend on; AstraZeneca has marketed it as the first drug in that class shown to help patients specifically because of when, not just what, they were treated with it.

Who it affects, and the caveats

Patients eligible for the drug are those with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who are already on a first-line aromatase inhibitor and CDK4/6 inhibitor combination and whose blood test turns up an ESR1 mutation. In practice, that means:

• Regular ctDNA blood testing becomes part of routine monitoring, not just something ordered after a scan shows the cancer has already progressed.
• Patients switch the hormone-blocking half of their regimen to the 75-milligram, once-daily camizestrant tablet while continuing the same CDK4/6 inhibitor, rather than starting an entirely new drug combination.
• Etcamah carries a boxed warning for irregular heart rhythm when combined with certain other medications, along with warnings about slowed heart rate and potential harm to a fetus, meaning cardiac history and pregnancy status will factor into who receives it.

Because the approval is accelerated rather than full, it was granted on the strength of progression-free survival data rather than confirmed proof that switching early extends how long patients live overall. AstraZeneca must run confirmatory studies, and the FDA can withdraw the approval if those studies fail to verify a clinical benefit. Data on overall survival from SERENA-6 were still immature at the time of AstraZeneca's initial analysis.

What officials and researchers are saying

"Women living with metastatic breast cancer face an uphill battle as their tumors continuously evolve to escape treatment. We owe them every weapon in our arsenal," Acting FDA Commissioner Kyle Diamantas said in the agency's announcement, adding that the approval gives patients "a targeted therapy designed specifically to overcome resistance."

Angelo de Claro, director of the FDA's Oncology Center of Excellence, was more cautious in the same release, calling it "the first FDA approval of a cancer therapy guided by the detection of a resistance mutation in circulating tumor DNA before imaging tests show that the disease is progressing," while noting that "additional evidence is needed to confirm clinical benefit."

Nicholas Turner, a professor of molecular oncology at the Institute of Cancer Research in London and a co-principal investigator on SERENA-6, was more emphatic when the trial data were first released, framing the approach as a departure from how oncologists have traditionally waited for disease progression before changing course.

"The results of the innovative SERENA-6 trial show that switching from an aromatase inhibitor to camizestrant in combination with any of the three CDK4/6 inhibitors after emergence of an ESR1 mutation more than halved the risk of disease progression or death and delayed deterioration in quality of life by nearly 18 months. This proactive approach exemplifies a new treatment strategy in oncology."

Not every oncologist has embraced the strategy uncritically. Commentary in the oncology trade press since the approval has focused on the same unresolved question the FDA itself flagged: whether treating a mutation found only in the blood, before it shows up on a scan, actually helps patients live longer, or whether it mainly starts treatment earlier without changing the ultimate outcome. That question is the subject of ongoing debate among specialists weighing how to incorporate ctDNA monitoring into everyday practice, including how often to test, who should pay for it, and how to counsel patients on results that arrive months before any physical sign of relapse.

What happens next

The FDA said full prescribing information for Etcamah would be posted to its Drugs@FDA database. Oncologists will need both the drug and the newly authorized Guardant360 CDx blood test to put the approval into practice, since the test is what identifies which patients carry the ESR1 mutation in the first place. Insurance coverage and out-of-pocket cost, not addressed in Friday's announcement, will shape how quickly the combination reaches patients outside major academic cancer centers, where ctDNA monitoring protocols are already more established.

The FDA's confirmatory-trial requirement means camizestrant's approval status will be revisited once longer-term survival data mature. The clinical trial supporting the approval, registered with the National Institutes of Health as SERENA-6, will continue to report survival follow-up data. In the meantime, wire coverage of Friday's clearance noted that the approval applies only to the subset of patients whose blood tests turn up the ESR1 mutation, not to breast cancer patients broadly, and that oncologists will need the newly authorized companion test to identify who qualifies.